戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 s remaining (often colistin, tigecycline, or aminoglycosides).
2  within 4 d after treatment with a synthetic aminoglycoside.
3 hB gene leads to decreased susceptibility to aminoglycosides.
4 er modifications on glucopyranosyl ring I of aminoglycosides.
5 uct removal with less toxicity than with the aminoglycosides.
6 st in the field of antibacterial amphiphilic aminoglycosides.
7 ensitizes hair cells to the toxic effects of aminoglycosides.
8 fference in inhibitory activity of different Aminoglycosides.
9  of large arteries and its resistance to all aminoglycosides.
10            Most ACSs included vancomycin and aminoglycosides.
11 al for sensors detecting the entire class of aminoglycosides.
12 te profile, including only 4,6-disubstituted aminoglycosides.
13 on of vancomycin without coadministration of aminoglycosides.
14 considering the frequent coadministration of aminoglycosides.
15 (6')lb genes, resulting in susceptibility to aminoglycosides.
16 e same dying hair cell following exposure to aminoglycosides.
17 the presence of nonsense suppressors such as aminoglycosides.
18             All but one infant also received aminoglycosides.
19 monstrated that all members of the bacterial aminoglycoside 2''-phosphotransferase IIIa (APH(2'')) am
20 ween ATP or GTP as the phosphate donor, with aminoglycoside 2''-phosphotransferase IVa (APH(2'')-IVa)
21                  The most frequent OADs were aminoglycosides (43 patients) and fluoroquinolones (20 p
22 atients were prescribed tetracyclines (49%), aminoglycosides (47%), and fluoroquinolones (41%).
23 ntibiotics, primarily amoxicillin (80%) with aminoglycosides (48%), were prescribed for a median dura
24 el class of potent antibacterial amphiphilic aminoglycosides (AAGs) with significant improved activit
25 bifunctional aminoglycoside-modifying enzyme aminoglycoside acetyltransferase(6')-Ie/aminoglycoside p
26                         The bacterial enzyme aminoglycoside acetyltransferase(6')-Ie/aminoglycoside p
27                       In these analyses, the aminoglycosides act as receptors, while RNA structures l
28 olding of cytosolic proteins as an effect of aminoglycoside action and reveal that chaperones, chaper
29 inoglycosides shed light on the mechanism of aminoglycosides action as antibiotics, no such data are
30                  These results indicate that aminoglycoside actions must be framed in the context of
31  whose upregulation causes resistance to the aminoglycoside (AG) antibiotic kanamycin A (KAN) in Myco
32            There is compelling evidence that aminoglycoside (AG) antibiotics can induce the mammalian
33 tb) efficiently multiacetylates a variety of aminoglycoside (AG) antibiotics.
34    Prior work showed that uptake of ototoxic aminoglycosides (AG) into hair cells requires functional
35  value of a number of antibiotics, including aminoglycosides, against intracellular pathogenic bacter
36                                              Aminoglycosides (AGs) are broad-spectrum antibiotics tha
37                                              Aminoglycosides (AGs) constitute a major family of poten
38            Cationic amphiphiles derived from aminoglycosides (AGs) have been shown to exhibit enhance
39                                              Aminoglycoside (AMG) antibiotics, prominent natural prod
40               Escherichia coli resistance to aminoglycosides, aminopenicillins, third generation ceph
41 t five classes of antibiotics (beta-lactams, aminoglycosides, amphenicols, sulfonamides, and tetracyc
42 , cell membrane function, detoxification and aminoglycoside and beta-lactam resistance.
43 our findings establish N1MS as a nonototoxic aminoglycoside and support targeted modification as a pr
44  patients is well tolerated, combined use of aminoglycoside and the non-toxic adjuvant L-arginine as
45 to oxidative stress, increased resistance to aminoglycosides and cationic antimicrobial peptides, and
46 ey are generally resistant to metronidazole, aminoglycosides and ciprofloxacin with L. acidophilus be
47 sistance to third generation cephalosporins, aminoglycosides and fluoroquinolones was moderately asso
48 ward decreasing microbial resistance against aminoglycosides and imipenem also was detected.
49                     By different mechanisms, aminoglycosides and inhibition of sulphate transport cau
50  beneficial for reducing hearing loss due to aminoglycosides and overstimulation.
51 otransducer channel and interactions between aminoglycosides and the bacterial ribosome.
52 ostatic interaction energies between various aminoglycosides and their binding sites correlate with e
53                      We studied six pairs of aminoglycosides and their corresponding ribosylated deri
54 tions and its per-ring contributions between aminoglycosides and their primary rRNA binding site.
55 litude of electrostatic interactions between aminoglycosides and their rRNA targets to introduce amin
56                                 The doses of aminoglycosides and vancomycin ranged from 0.25 to 4.8 g
57 rapy with broad-spectrum beta-lactams and/or aminoglycosides and/or fluoroquinolones was started.
58 ncluding sulfonamides, fluoroquinolones, and aminoglycosides), and higher diversity in both genotype
59  combination antibiotic therapy including an aminoglycoside, and early indwelling catheter removal).
60 fections, but it also reduced cephalosporin, aminoglycoside, and vancomycin exposure and reduced the
61 he other containing both sulfonamides, three aminoglycosides, and tetracycline.
62  of heat shock proteins (HSPs) inhibits both aminoglycoside- and cisplatin-induced hair cell death an
63 boxamide, 1 (ORC-001), as protective against aminoglycoside antibiotic (AGA)-induced hair cell death.
64  ANG's nuclear translocation by neomycin, an aminoglycoside antibiotic (not G418-neomicin), resulted
65 rains to complement-mediated killing and the aminoglycoside antibiotic amikacin.
66 555A>G predisposes to hearing loss following aminoglycoside antibiotic exposure in an idiosyncratic d
67                                          The aminoglycoside antibiotic hygromycin B (Hyg) inhibits pr
68           The 6-aminoglucosamine ring of the aminoglycoside antibiotic neomycin B (ring II) was conju
69        A series of 20 4'-O-glycosides of the aminoglycoside antibiotic paromomycin were synthesized a
70 ng the efficacy of PTC124 with the classical aminoglycoside antibiotic read-through agent geneticin (
71                                          The aminoglycoside antibiotic streptomycin disrupts decoding
72          Paromomycin (PAR), a broad-spectrum aminoglycoside antibiotic, has been shown in recent year
73 on during the biosynthesis of gentamicin, an aminoglycoside antibiotic.
74 ted that bactericidal antibiotics, including aminoglycoside antibiotics (AGAs), and toxic small molec
75 ma membrane, and increased susceptibility to aminoglycoside antibiotics and cationic antimicrobials.
76  drugs with ototoxic side effects, including aminoglycoside antibiotics and cisplatin.
77 saccharide Pel, which protects bacteria from aminoglycoside antibiotics and contributes to biofilm ar
78                                              Aminoglycoside antibiotics are known toxins to cochlear
79                                  Exposure to aminoglycoside antibiotics can lead to the generation of
80                                    Different aminoglycoside antibiotics combined with different sulph
81 almost half of a century, we have known that aminoglycoside antibiotics corrupt ribosomes, causing tr
82                                              Aminoglycoside antibiotics have been proposed for restor
83 in that can act synergistically and detoxify aminoglycoside antibiotics highly efficiently.
84 l subunit RNA of the bacterial ribosome, the aminoglycoside antibiotics inhibit protein synthesis, ca
85                                              Aminoglycoside antibiotics interfere with ribosomal func
86 aration of a series of four analogues of the aminoglycoside antibiotics neomycin and paromomycin is d
87         After destruction of hair cells with aminoglycoside antibiotics or noise, SGNs gradually die.
88 an improved understanding of how amphiphilic aminoglycoside antibiotics that bind to negatively charg
89 ility to fluoroquinolone, cephalosporin, and aminoglycoside antibiotics using disk diffusion assays.
90 romising avenue for the development of novel aminoglycoside antibiotics with improved efficacy and re
91 ues, such as hyperosmolarity and presence of aminoglycoside antibiotics, (ii) narrowed their metaboli
92 sh lateral line hair cells after exposure to aminoglycoside antibiotics, a well characterized hair ce
93 sses of ototoxic drugs are cisplatin and the aminoglycoside antibiotics, both of which are toxic to m
94 on-derived kinase that confers resistance to aminoglycoside antibiotics, in Escherichia coli under se
95 ays a significant role in resistance against aminoglycoside antibiotics, is controlled by a translati
96                                An example is aminoglycoside antibiotics, which by binding to ribosoma
97           Clinical use of 2-deoxystreptamine aminoglycoside antibiotics, which target the bacterial r
98  fusion system, with decreased resistance to aminoglycoside antibiotics.
99 ce, to develop a sensor for the detection of aminoglycoside antibiotics.
100 iosynthesis of 2-deoxystreptamine-containing aminoglycoside antibiotics.
101 miting factor in the clinical application of aminoglycoside antibiotics.
102 anism by which bacteria confer resistance to aminoglycoside antibiotics.
103 ment (SELEX) to isolate RNA aptamers against aminoglycoside antibiotics.
104 high-level resistance to a broad spectrum of aminoglycoside antibiotics.
105 ts induced on lipid membranes by amphiphilic aminoglycoside antibiotics.
106 es for understanding the structural basis of aminoglycoside-aptamer recognition highlighted by the SE
107                                              Aminoglycosides are a well known antibiotic family used
108 COL7A1, and previous studies have shown that aminoglycosides are able to overcome RDEB PTC mutations
109                                              Aminoglycosides are antibiotic drugs that act through bi
110                                              Aminoglycosides are chemically diverse, broad-spectrum a
111 materials that are enabled by lipid-modified aminoglycosides are demonstrated.
112                                              Aminoglycosides are mostly known as highly potent, broad
113 horylation of 4,5-disubstituted and atypical aminoglycosides are negligible and thus these antibiotic
114                                              Aminoglycosides are potent antibacterials, but therapy i
115                                              Aminoglycosides are potent, broad spectrum, ribosome-tar
116                                        The 3-aminoglycosides are ubiquitous in biologically important
117                                              Aminoglycosides are widely used broad-spectrum antibioti
118 chaperonin expression sensitized bacteria to aminoglycosides as measured by reduced minimum inhibitor
119 itro screening of linear polyamine-based and aminoglycoside-based polymer libraries identified severa
120                             In contrast, the aminoglycoside-based polymer paromomycin-BGDE, enhanced
121 ibitory concentrations of an investigational aminoglycoside, belonged to multi-locus sequence type 94
122 gnificantly contributed to the resistance to aminoglycosides, beta-lactams, and macrolides observed i
123  well as MST markers and resistance genes to aminoglycosides, beta-lactams, and tetracycline.
124                                     Although aminoglycosides bind helix69 of the bacterial large subu
125       The conformational changes and similar aminoglycoside binding affinities observed for human mit
126 st possible modifications that could enhance aminoglycoside binding affinity.
127                                 In addition, aminoglycoside binding enhanced conformational stability
128 bility, base stacking, and conformation upon aminoglycoside binding to the human cytoplasmic helix69
129 human mitochondrial and E. coli helix69 upon aminoglycoside binding, as compared with human cytoplasm
130 ncapsulated RI promotes the protection of an aminoglycoside-binding RNA E-AB sensor up to 6 h, enabli
131 at 3.3- to 3.7-A resolution, reveal multiple aminoglycoside-binding sites within the large and small
132 prD3, is responsible for 3'-deoxygenation in aminoglycoside biosynthesis.
133 methyltransferases confer resistance to most aminoglycosides, but discriminating their activity from
134  resistant to rifampin, fluoroquinolones, or aminoglycosides, but for which Sanger sequencing found n
135 mework for further development of less toxic aminoglycosides by hypothesis-driven chemical synthesis.
136  that antibacterial activity and toxicity of aminoglycosides can be dissected from their suppression
137                           Here, we show that aminoglycosides cause cytosolic protein misfolding and t
138                            Here we show that aminoglycosides chemically related to neomycin-paromomyc
139 strate clinical benefits of beta lactam plus aminoglycoside combination therapy compared to beta lact
140 , Dutch guidelines recommend beta-lactam and aminoglycoside combination therapy or carbapenem monothe
141              When compared with monotherapy, aminoglycoside-containing combination therapy did not de
142 rategies synthesized were monotherapy versus aminoglycoside-containing combination therapy; antipseud
143 ensitizes hair cells to the toxic effects of aminoglycosides, contrasting with current models of exci
144           When GJIC was inhibited during the aminoglycoside damage paradigm, the epithelial repair re
145 the initial epithelial repair process in the aminoglycoside-damaged BP.
146       3',6-Dinonyl neamine is an amphiphilic aminoglycoside derivative active against Pseudomonas aer
147 r rational design of new, and more specific, aminoglycoside derivatives as potential therapeutic agen
148 l structurally related natural and synthetic aminoglycoside derivatives.
149                            Treatment with an aminoglycoside-diuretic combination produced loss of all
150             After exposure of live larvae to aminoglycosides, dying hair cells undergo a transient in
151                       Based on the increased aminoglycoside efficiency under alkaline conditions, we
152          Here, we hypothesized that reducing aminoglycoside entry into hair cells via mechanotransduc
153                  The distinct impacts of the aminoglycosides examined suggest that their chemical com
154 engers conferred superior protection against aminoglycoside exposure compared with identical, untarge
155 lly inherited hearing loss in the absence of aminoglycoside exposure or any other clinical features (
156                                       During aminoglycoside exposure to exponential cultures, chapero
157  Ca(2+) effectors mitigates toxic effects of aminoglycoside exposure.
158 potential to ameliorate the toxic effects of aminoglycoside exposure.
159 ultiple antibiotics, including beta-lactams, aminoglycosides, fluoroquinolones, and polymyxins.
160 antibiotic therapy with a beta-lactam and an aminoglycoside for the treatment of gram-negative bacter
161 ribosomal A site: Geneticin (G418), a potent aminoglycoside for the treatment of leishmaniasis at a 2
162 se of the guanidinylated ligand, but the two aminoglycoside fragments seem to interfere with its acco
163 reviously exposed to long-term macrolides or aminoglycosides, further indicating cross-infection.
164 liver regulates Se metabolism, we tested the aminoglycosides G418 and gentamicin in hepatoma cell lin
165 tive release factors, or the presence of the aminoglycoside gentamicin.
166 inst eight antibiotic classes (beta-lactams, aminoglycosides, glycopeptides, chloramphenicols, tetrac
167                               Recently, some aminoglycosides have been clinically approved and are cu
168                                              Aminoglycosides have been proposed as therapies for gene
169 other classes of antibiotic drugs, including aminoglycosides, have become common.
170 to inactivate an unusually broad spectrum of aminoglycosides, including 4,6- and 4,5-disubstituted an
171 asis; however the molecular details by which aminoglycosides induce their deleterious effect on Leish
172 Ca(2+) homeostasis play an essential role in aminoglycoside-induced hair cell death, and indicate sev
173 cellular Ca(2+) dynamics in real time during aminoglycoside-induced hair cell death.
174 ondrial calcium drives ROS generation during aminoglycoside-induced hair cell death.
175 f a novel stress pathway that contributes to aminoglycoside-induced hair cell degeneration.
176 dy the role of protein synthesis activity in aminoglycoside-induced hair cell stress.
177 und therapy also provided protection against aminoglycoside-induced hearing loss.
178 erized a novel otoprotectant working against aminoglycoside-induced hearing loss.
179 vide structural and functional insights into aminoglycoside-induced impacts on the eukaryotic ribosom
180        Better understanding of the origin of aminoglycoside-induced ROS could focus the development o
181                          We demonstrate that aminoglycosides inhibit protein synthesis in hair cells
182 s into the structural elements important for aminoglycoside inhibitory activities and selectivity for
183 n of kanamycin B converts this antibacterial aminoglycoside into a novel antifungal agent.
184 rs 1 and 3 (eRF1 and eRF3) or by introducing aminoglycosides into the cells.
185 ncorporating two exhaustively guanidinylated aminoglycosides into the receptor library.
186           However, the effectiveness of this aminoglycoside is still limited by its inability to pene
187 cal gentamicin, a mixture of several related aminoglycosides, is a frequently used antibiotic in huma
188  of the 4,6-disubstituted 2-deoxystreptamine aminoglycoside kanamycin B led to improved selectivity f
189 illin and penicillin), quinolone (enoxacin), aminoglycoside (kanamycin and neomycin), and polykeptide
190 oside 2''-phosphotransferase IIIa (APH(2'')) aminoglycoside kinase family are unique in their ability
191 that ATP is the canonical phosphate donor in aminoglycoside kinases and protein kinases, it was recen
192                                          The aminoglycoside kinases are important antibiotic resistan
193  members of the APH(2'') subfamily and other aminoglycoside kinases, rationalize the different substr
194 g templates are conserved in other bacterial aminoglycoside kinases, whereas in the structurally rela
195 inding that apramycin, a structurally unique aminoglycoside licensed for veterinary use, shows little
196 ion of oritavancin with other agents such as aminoglycosides may offer promise and deserves further i
197                            The efficiency of aminoglycoside-mediated readthrough depends on the type
198 anosine lesions, whereas the cytotoxicity of aminoglycosides might additionally result from mistransl
199 ay and, thus, represent a potential class of aminoglycoside mimetics.
200 ycosides and their rRNA targets to introduce aminoglycoside modifications that would enhance their bi
201                             The bifunctional aminoglycoside-modifying enzyme aminoglycoside acetyltra
202 ere investigated further for the presence of aminoglycoside-modifying enzyme genes using multiplex PC
203 t discriminating their activity from that of aminoglycoside-modifying enzymes (AMEs) is challenging u
204  problems, we engineered Pentobra, a peptide-aminoglycoside molecule that has multiple mechanisms of
205  present crystal structures of two different aminoglycoside molecules bound to a model of the Leishma
206 ry of three dialkyl derivatives of the small aminoglycoside neamine active against susceptible and re
207 philic 3',6-dialkyl derivatives of the small aminoglycoside neamine as broad spectrum antibacterial a
208 ization of such Janus compounds with a small aminoglycoside, neamine, and its guanidinylated analogue
209 trum antibiotics, or with the gut-restricted aminoglycoside neomycin alone, accelerated phagocyte tur
210 4'-O-glycosylation blocking the action of 4'-aminoglycoside nucleotidyl transferases by the use of re
211 orylation through a family of enzymes called aminoglycoside O-phosphotransferases (APHs) is a major m
212                 Some enriched genes, such as aminoglycoside O-phosphotransferases, confer resistance
213 ngs suggest that the interfering activity of aminoglycosides on selenoprotein biosynthesis can be sev
214 ide an acceptable alternative to intravenous aminoglycosides or long courses of tetracyclines where c
215 recovered uneventfully, without accompanying aminoglycosides or tetracyclines.
216 f concurrent resistance to fluoroquinolones, aminoglycosides, or macrolides (P < .001).
217                                              Aminoglycoside ototoxicity occurs both in a sporadic dos
218 ning the role of fractalkine signaling after aminoglycoside ototoxicity or acoustic trauma.
219 r understanding of the mechanisms underlying aminoglycoside ototoxicity remains limited.
220 ing up novel strategies to prevent and treat aminoglycoside ototoxicity.
221 antibacterial activity can be dissected from aminoglycoside ototoxicity.
222 the mitochondrial ribosome (mitoribosome) in aminoglycoside ototoxicity.
223 zyme aminoglycoside acetyltransferase(6')-Ie/aminoglycoside phosphotransferase(2'')-Ia possesses an N
224 zyme aminoglycoside acetyltransferase(6')-Ie/aminoglycoside phosphotransferase(2'')-Ia, or AAC(6')-Ie
225 a putative kinase belonging to the family of aminoglycoside phosphotransferases suggested that AGXT2L
226 '')-Ia domain of this enzyme is unique among aminoglycoside phosphotransferases, having the ability t
227   We performed a dose-ranging study with the aminoglycoside plazomicin against Pseudomonas aeruginosa
228                        Among these are a new aminoglycoside (plazomicin), anti-MRSA cephalosporins (c
229      Our data indicate that 4'-O-substituted aminoglycosides possess increased selectivity towards ba
230 group from SAM is transferred to Cbl and the aminoglycoside product during the course of the reaction
231            We demonstrate that arbekacin, an aminoglycoside refractory to most AMEs, can rapidly dete
232 f tetracycline, multidrug, erythromycin, and aminoglycoside resistance genes were discovered in these
233 min, bacitracin, vancomycin, beta-lactam and aminoglycoside resistance genes were the top seven most
234 iae that includes two beta-lactamase and two aminoglycoside resistance genes.
235 C(6')-Ie/APH(2'')-Ia, is the major source of aminoglycoside resistance in gram-positive bacterial pat
236 subspecies and determining the macrolide and aminoglycoside resistance levels of 50 Mycobacterium abs
237 nal failure and regardless of the high-level aminoglycoside resistance status of E. faecalis.
238 nd "not cured." Strong biofilm formation and aminoglycoside resistance were associated with a "not-cu
239 ntly lower during SDD compared with SOD; for aminoglycoside resistance, average prevalence was 5.6% (
240 ISPR)/Cas9 system, and in vivo selection for aminoglycoside resistance.
241 on upon streptomycin treatment and increased aminoglycoside resistance.
242 cluding the extended-spectrum ss-lactam- and aminoglycoside-resistance genes, were identified in the
243 0S recognition by the novel plasmid-mediated aminoglycoside-resistance rRNA methyltransferase A (NpmA
244  new molecular framework for the activity of aminoglycoside-resistance rRNA methyltransferases that m
245 te and preferable in treating non-high-level aminoglycoside-resistant E faecalis infective endocardit
246 entions the prevalence of rectal carriage of aminoglycoside-resistant gram-negative bacteria increase
247 ia but a more pronounced gradual increase in aminoglycoside-resistant gram-negative bacteria.
248                         C3'-deoxygenation of aminoglycosides results in their decreased susceptibilit
249 rt to crystallographically derived models of aminoglycoside-ribosome interactions.
250 ructed the aspherical electron density of 12 aminoglycoside-RNA complexes from the atomic parameters
251 s and PCA loading factors revealed trends in aminoglycoside:RNA recognition, including the importance
252 he first systematic development of the novel aminoglycoside (S)-11 exhibiting similar in vitro and ex
253  natural or semisynthetic pseudodisaccharide aminoglycoside scaffolds containing an equatorial amine
254                   For the pseudodisaccharide aminoglycoside scaffolds neamine and nebramine, ribosyla
255 ns leading to maternally inherited deafness, aminoglycoside sensitivity and diabetes.
256 es of the bacterial ribosome in complex with aminoglycosides shed light on the mechanism of aminoglyc
257                     Compared with the parent aminoglycoside sisomicin, all 9 derivatives displayed no
258                    We show that this lack of aminoglycoside specificity is a common property of aptam
259  bNOS-deficient strains gained resistance to aminoglycosides, suggesting that the role of bNOS in ant
260 ically engineered to carry the mitoribosomal aminoglycoside-susceptibility A1555G allele.
261  In the search for antimicrobial amphiphilic aminoglycosides targeting bacterial membranes, we report
262                               Instead, these aminoglycosides tend to stimulate an intrinsic GTPase ac
263   AAS and aerobic systems especially reduced aminoglycoside, tetracycline, and beta-lactam ARG levels
264 ugs in known classes such as new quinolones, aminoglycosides, tetracyclines, and beta-lactams have be
265 ng protein synthesis inhibitors (macrolides, aminoglycosides, tetracyclines, lincosamides, and chlora
266 emonstrate that streptomycin, a bactericidal aminoglycoside that increases ribosomal mistranslation,
267  have identified highly charged compounds or aminoglycosides that commonly have modest selectivity.
268 tions in the drug-binding site, resulting in aminoglycosides that interact poorly with the drug-bindi
269        Because of the nephrotoxic effects of aminoglycosides, the Danish guidelines on infective endo
270 st on the effects of short-course adjunctive aminoglycoside therapy in sepsis patients with organ fai
271                       Early beta-lactam plus aminoglycoside therapy was used in 391 (91.3%) patients.
272  rifampicin, fluoroquinolones and injectable aminoglycosides, they would be suitable for treating man
273                  The ability of a particular aminoglycoside to inhibit protein synthesis and to activ
274                            The propensity of aminoglycosides to induce miscoding errors that suppress
275 e strong and differential binding ability of aminoglycosides to RNA structures can be used to classif
276 ination with selection for resistance to the aminoglycoside tobramycin, the aac(6')-Ie/aph(2'')-Ia ge
277 le vectors, derived from naturally occurring aminoglycoside tobramycin, was prepared using improved s
278                                     However, aminoglycoside toxicity will likely prevent widespread c
279  binding event is important to understanding aminoglycoside toxicity.
280 tated survival but did not promote growth of aminoglycoside-treated bacteria.
281 mal A site in control, ataluren-treated, and aminoglycoside-treated cells.
282                        Focused analyses with aminoglycoside-treated patients are needed next to evalu
283                                         Both aminoglycoside treatment and acoustic overstimulation le
284 ncy (aOR = 2.4; 95% CI = 1.0-5.8; P = .046), aminoglycoside use (aOR = 4.7; 95% CI = 2.2-9.8; P < .00
285 e; 95% confidence interval [CI], 0.99-1.21), aminoglycoside use (OR, 2.33; 95% CI, 1.17-4.57), resist
286                                              Aminoglycoside use and early catheter removal in patient
287 ical gatifloxacin, prophylaxis using topical aminoglycoside was ineffective (OR, 1.97; CI, 1.17-3.31)
288 nt trends; specifically, the adjusted HR for aminoglycosides was 1.05 (95% CI, .51-2.16).
289                               In both media, aminoglycosides were more efficacious in the 3-D cell mo
290  (rifampin, isoniazid, fluoroquinolones, and aminoglycosides) were analyzed for markers.
291 , gyrA (ofloxacin/fluoroquinolone), and rrs (aminoglycosides)-were amplified and sequenced, and resul
292                             Gentamicin is an aminoglycoside widely used in treatments of, in particul
293 APH(2'')-Ia phosphorylates 4,6-disubstituted aminoglycosides with high efficiency (k(cat)/K(m) = 10(5
294  ototoxicity, and therefore we synthesized 9 aminoglycosides with modifications based on biophysical
295         Our work demonstrates that equipping aminoglycosides with selective membrane activity is a vi
296 and cocaethylene with similar affinities and aminoglycosides with similar or higher affinities in a m
297 veal the interactions of distinct classes of aminoglycosides with the 80S eukaryotic ribosome.
298 ra combines the potent ribosomal activity of aminoglycosides with the bacteria-selective membrane-per
299         However, the sites of interaction of aminoglycosides with the eukaryotic ribosome and their m
300 EX rounds were toggled against four pairs of aminoglycosides with the goal of isolating reagents that

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top